(Q38109019)

29 August 2017

Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study (English)

1 reference

multicenter clinical trial

29 August 2017

0 references

0 references

Chang Kyun Lee

10

0 references

Seong Woo Jeon

object named as

Seong Woo Jeon

3

0 references

Byong Duk Ye

object named as

Byong Duk Ye

4

0 references

Jae Hee Cheon

object named as

Jae Hee Cheon

2

0 references

author name string

Jin Ha Lee

1

1 reference

29 August 2017

Suk-Kyun Yang

5

1 reference

29 August 2017

Young-Ho Kim

6

1 reference

29 August 2017

Kang-Moon Lee

7

1 reference

29 August 2017

Jong Pil Im

8

1 reference

29 August 2017

Joo Sung Kim

9

1 reference

29 August 2017

Hyo Jong Kim

11

1 reference

29 August 2017

Eun Young Kim

12

1 reference

29 August 2017

Kyeong Ok Kim

13

1 reference

29 August 2017

Byung Ik Jang

14

1 reference

29 August 2017

Won Ho Kim

15

1 reference

29 August 2017

1 August 2013

1 reference

Inflammatory Bowel Diseases

29 August 2017

1 reference

29 August 2017

19

1 reference

29 August 2017

9

1 reference

29 August 2017

1833-1838

1 reference

Intestinal involvement in Behçet's disease: review of 136 surgical cases in the Japanese literature

29 August 2017

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Behçet disease (Behçet syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Gastrointestinal manifestations of Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Recent advances of endoscopy in inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Cytokines in the colon of a patient with Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Intestinal Behçet's disease: epidemiology, pathophysiology and potential of mesalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Thalidomide for treatment of intestinal involvement of juvenile-onset Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Clinical course of intestinal Behcet's disease during the first five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Predictors of response to infliximab in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behcet's disease (BD) in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E31828F19C9

10.1097/MIB.0B013E31828F19C9

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference